In this episode of the Data and Biotech Podcast, host Ross Katz sits down with Dr. Jonathan Usuka to discuss Usuka’s extensive background in bioinformatics and genomics, leading to his current role as CEO of Sapient. 

The conversation dives into the importance of deep molecular characterization of diseases, the role of proteomics and metabolomics in drug discovery, and the gaps between real-world data and clinical trial data. 

As a leader with a small but impactful team, Jonathan discusses the complexities of the dark proteome and metabolites, emphasizing the opportunity for deeper biological insights in pharmaceutical research using repeated, deep profiling of the same cohorts of patients. Jonathan also explores how advancements in computational approaches allow Sapient to build a robust data foundation for insight generation in biopharma. 

​​What You'll Learn in This Episode:

• The significance of longitudinal patient sampling
• Why we need robust conclusions in biotechnology 
• How the role of the FDA is evolving for drug approval and personalized medicine applications

Connect with Our Guest:

• Sponsor:CorrDyn, a data consultancy
• Find out more about Sapient 
• Connect with Dr. Jonathan Usuka on LinkedIn

Connect with Us:

• Follow the podcast for more insightful discussions on the latest in biotech and data science.
• Subscribe and leave a review if you enjoyed this episode!